Department of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, School of Medicine , Shanghai Jiao Tong University , Shanghai 200025 , China.
J Med Chem. 2019 Jan 10;62(1):24-45. doi: 10.1021/acs.jmedchem.7b01844. Epub 2018 Feb 26.
G-protein-coupled receptors (GPCRs) are the largest class of signaling receptors that are most frequently targeted by therapeutic drugs. Allosteric modulators bound to GPCRs at allosteric sites provide the potential for differential selectivity and improved safety compared with traditional orthosteric ligands. The recent breakthroughs in GPCR structural biology have made structures of GPCRs from classes A, B, C, and F complexed with small-molecule allosteric modulators available. Knowledge of the detailed receptor-modulator interactions at the allosteric sites is useful for structure-based GPCR drug design of novel therapeutics. This Perspective comprehensively summarizes the current status of structural complexes between GPCRs and their small-molecule allosteric modulators, particularly the key receptor-modulator interactions at the allosteric sites. Then, the structural diversity of allosteric sites across four GPCR subfamilies is compared. This study is expected to contribute to the design of GPCR allosteric drugs with an improved therapeutic action.
G 蛋白偶联受体(GPCRs)是最大的信号转导受体家族,也是最常被治疗药物靶向的受体。与传统的正位配体相比,与 GPCR 上的变构位点结合的变构调节剂为差异化选择性和提高安全性提供了潜力。GPCR 结构生物学的最新突破使得 A、B、C 和 F 类 GPCR 与小分子变构调节剂的复合物结构得以实现。了解变构位点处的详细受体-调节剂相互作用对于基于结构的新型治疗药物的 GPCR 药物设计非常有用。本观点全面总结了 GPCR 与其小分子变构调节剂之间的结构复合物的现状,特别是变构位点处的关键受体-调节剂相互作用。然后,比较了四个 GPCR 亚家族的变构位点的结构多样性。这项研究有望有助于设计具有改善治疗作用的 GPCR 变构药物。